Ian Woo
Mr. Ian Ying Woo is an experienced biopharma finance professional bringing substantial strategy, capital markets and operations and management expertise to NovaBridge. Currently, Mr. Woo is President, Chief Financial Officer and Executive Director of Everest Medicines Limited (HKEX: 1952), and also serves as an operating partner of CBC Group. He has recently served as an independent director and chairman of the audit committee of Prenetics Global Limited (Nasdaq: PRE). Before that, Mr. Woo’s held the role of managing director of CBC Group. Prior to that, Mr. Woo was a managing director in the global healthcare group of Lazard Frères & Co. LLC, working in the New York and Hong Kong offices. Throughout his investment banking career, Mr. Woo helped to raise over US$1 billion in equity financings and advised on merger and acquisition transactions aggregating more than US$35 billion in value.
Mr. Woo received his Bachelor of Science in Biology from Tufts University, his Master of Arts in Cellular, Molecular and Biomedical studies from the Columbia University Graduate School of Arts and Sciences and his Master of Business Administration from the Columbia University Graduate School of Business.